Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016;39:1972 (Q55192252)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016;39:1972 |
scientific article |
Statements
1 reference
Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016;39:1972 (English)
1 reference
1 reference
Julio Rosenstock
1 reference
Richard M Bergenstal
1 reference
Vanita R Aroda
1 reference
Carol Wysham
1 reference
Jeffrey Unger
1 reference
Guillermo González-Gálvez
1 reference
Akane Takami
1 reference
Hailing Guo
1 reference
Elisabeth Niemoeller
1 reference
Elisabeth Souhami
1 reference
LixiLan-L Trial Investigators
1 reference
20 April 2017
1 reference
1 reference
40
1 reference
6
1 reference
809
1 reference
Identifiers
1 reference
1 reference
1 reference